Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea

Annals of Pharmacotherapy

Volumn 42, Issue 6, 2008, Pages 827-835

  Garey, Kevin W ^a   Salazar, Miguel ^b   Shah, Dhara ^a   Rodrigue, Richard ^a   DuPont, Herbert L ^c,d  

^a UNIVERSITY OF HOUSTON   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d St Luke's Episcopal Hospital

Author keywords

Clostridium difficile diarrhea; Rifamycin

Indexed keywords

BACITRACIN; METRONIDAZOLE; NITAZOXANIDE; PLACEBO; RIFALAZIL; RIFAMPICIN; RIFAMYCIN; RIFAXIMIN; VANCOMYCIN;

AGAR DILUTION; ANTIBIOTIC PROPHYLAXIS; BACKACHE; BACTERIAL INFECTION; BACTERIUM ISOLATE; BILIARY EXCRETION; CLINICAL STUDY; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TOLERABILITY; FECES CULTURE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; MICROBIAL SENSITIVITY TESTS; RIFAMYCINS; SEVERITY OF ILLNESS INDEX;

EID: 44649148512     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K675     Document Type: Review

References (41)

1. Cloud J, Kelly CP. Update on Clostridium difficile associated disease. Curr Opin Gastroenterol 2007;23:4-9.
2. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5:549-57.
3. Surowiec D, Kuyumjian AG, Wynd MA, Cicogna CE. Past, present, and future therapies for Clostridium difficile-associated disease. Ann Pharmacother 2006;40:2155-63. Epub 5 Dec 2006. DOI 10.1345/aph.1H332
4. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027-34; quiz 35-6.
5. Anton PM, O'Brien M, Kokkotou E, et al. Rifalazil treats and prevents relapse of Clostridium difficile-associated diarrhea in hamsters. Antimicrob Agents Chemother 2004;48:3975-9.
6. Bacon AE, McGrath S, Fekety R, Holloway WJ. In vitro synergy studies with Clostridium difficile. Antimicrob Agents Chemother 1991;35:582-3.
7. Bishara J, Bloch Y, Garty M, Behor J, Samra Z. Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis 2006;54:141-4.
8. Bourgault AM, Lamothe F, Loo VG, Poirier L. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Quebec, Canada. Antimicrob Agents Chemother 2006;50:3473-5.
9. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-9.
10. Marchese A, Salerno A, Pesce A, Debbia EA, Schito GC. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 2000;46:253-66.
11. Ripa S, Mignini F, Prenna M, Falcioni E. In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. Drugs Exp Clin Res 1987;13:483-8.
12. Ensminger PW, Counter FT, Thomas LJ, Lubbehusen PP. Susceptibility, resistance development, and synergy of antimicrobial combinations against Clostridium difficile. Curr Microbiol 1982;7:59-62.
13. Barbut F, Deere D, Burghoffer B, et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999;43:2607-11.
14. Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 1983;11:427-33.
15. Jiang ZD, Ke S, Palazzine E, et al. In vitro activity and fecal concentrations of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44:2205-6.
16. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327-41.
17. Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005;3:201-11.
18. Rothstein DM, Shalish C, Murphy CK, Sternlicht A, Campbell LA. Development potential of rifalazil and other benzoxazinorifamycins. Expert Opin Investig Drugs 2006;15:603-23.
19. Williams R, Bass N. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. Rev Gastroenterol Disord 2005;5(suppl 1):S10-8.
20. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14:51-6.
21. Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999;44:1220-1.
22. Rizzello F, Gionchetti P, Venturi A, et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 1998;54:91-3.
23. Tedesco F, Markham R, Gurwith M, Christie D, Bartlett JG. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978;2:226-8.
24. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986;27:1169-72.
25. Pentikis HS, Connolly M, Trapnell CB, Forbes WP, Bettenhausen DK. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy 2007;27:1361-9.
26. Hosoe K, Mae T, Konishi E, et al. Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrob Agents Chemother 1996;40:2749-55.
27. Mae T, Hosoe K, Yamamoto T, et al. Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog. Xenobiotica 1998;28:759-66.
28. Kokkotou E, Mustafa N, O'Brien M, Pothoulakis C, Kelly CP. Rifaximin: a novel nonabsorbed antibiotic therapy for Clostridium difficile-associated diarrhea. Presented at: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, Washington, DC. 2005.
29. Nomura K, Matsumoto Y, Yoshida N, et al. Successful treatment with rifampin for fulminant antibiotics-associated colitis in a patient with non-Hodgkin's lymphoma. World J Gastroenterol 2004;10:765-6.
30. Buggy BP, Fekety R, Silva J Jr. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 1987;9:155-9.
31. Garey KW, Jiang ZD, Bellard A, DuPont HL. Rifaximin in treatment of recurrent Clostridium difficile associated diarrhea, an uncontrolled pilot study. J Clin Gastroenterol 2008 (Epub ahead of print).
32. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile- associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-8.
33. Boero M, Berti E, Morgando A, Verme G. Treatment for colitis caused by Clostridium difficile: results of a randomized, open-label study of rifaximin vs. vancomycin. Microbiologia Medica 1990;5:74-7.
34. Lagrotteria D, Holmes S, Smieja M, Smaill F, Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:547-52.
35. Boriello SP, Jones RH, Phillips I. Rifampicin-associated pseudomembranous colitis. Br Med J 1980;281:1180-1.
36. Byrd RP Jr, Roy TM, Ossorio MA, Fields CL. Delayed onset of pseudomembranous colitis after rifampin therapy. South Med J 1997;90:644-6.
37. Fournier G, Orgiazzi J, Lenoir B, Dechavanne M. Pseudomembranous colitis probably due to rifampicin. Lancet 1980;1:101.
38. Jung SW, Jeon SW, Do BH, et al. Clinical aspects of rifampicin-associated pseudomembranous colitis. J Clin Gastroenterol 2007;41:38-40.
39. O'Connor RP, Silva J Jr, Fekety R. Rifampicin and antibiotic-associated colitis. Lancet 1981;1:499.
40. Chen YX, Cabana B, Kivel N, Michaelis A. Effect of food on the pharmacokinetics of rifalazil, a novel antibacterial, in healthy male volunteers. J Clin Pharmacol 2007;47:841-9.
41. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000;12:203-8.